MX2021012392A - Compuestos, composiciones y metodos. - Google Patents

Compuestos, composiciones y metodos.

Info

Publication number
MX2021012392A
MX2021012392A MX2021012392A MX2021012392A MX2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A
Authority
MX
Mexico
Prior art keywords
methods
compositions
compounds
tautomer
stereoisomer
Prior art date
Application number
MX2021012392A
Other languages
English (en)
Spanish (es)
Inventor
Jianwen A Feng
Anthony A Estrada
Zachary K Sweeney
Vicente Fidalgo Javier De
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2021012392A publication Critical patent/MX2021012392A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021012392A 2019-04-11 2020-04-10 Compuestos, composiciones y metodos. MX2021012392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832775P 2019-04-11 2019-04-11
PCT/US2020/027742 WO2020210684A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
MX2021012392A true MX2021012392A (es) 2021-11-12

Family

ID=72752101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012392A MX2021012392A (es) 2019-04-11 2020-04-10 Compuestos, composiciones y metodos.

Country Status (19)

Country Link
US (1) US12358896B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953348B1 (cg-RX-API-DMAC7.html)
JP (1) JP7623294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102962366B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939294A (cg-RX-API-DMAC7.html)
AR (1) AR118641A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020272045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020027A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136447A1 (cg-RX-API-DMAC7.html)
DK (1) DK3953348T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192530A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018383T3 (cg-RX-API-DMAC7.html)
IL (1) IL287120B2 (cg-RX-API-DMAC7.html)
MA (1) MA55624A (cg-RX-API-DMAC7.html)
MX (1) MX2021012392A (cg-RX-API-DMAC7.html)
SG (1) SG11202111058XA (cg-RX-API-DMAC7.html)
TW (1) TWI851710B (cg-RX-API-DMAC7.html)
WO (1) WO2020210684A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107499B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AU2021371697B2 (en) * 2020-10-29 2024-10-24 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Also Published As

Publication number Publication date
ES3018383T3 (es) 2025-05-16
EP3953348B1 (en) 2024-12-18
CN113939294A (zh) 2022-01-14
AU2020272045A1 (en) 2021-10-28
IL287120B1 (en) 2025-02-01
BR112021020027A2 (pt) 2021-12-07
TWI851710B (zh) 2024-08-11
JP7623294B2 (ja) 2025-01-28
DK3953348T3 (da) 2025-03-17
WO2020210684A1 (en) 2020-10-15
JP2022526015A (ja) 2022-05-20
AR118641A1 (es) 2021-10-20
KR102962366B1 (ko) 2026-05-11
TW202104213A (zh) 2021-02-01
AU2020272045B2 (en) 2026-01-15
EP3953348A1 (en) 2022-02-16
CA3136447A1 (en) 2020-10-15
EA202192530A1 (ru) 2022-03-15
IL287120B2 (en) 2025-06-01
US20220220094A1 (en) 2022-07-14
EP3953348A4 (en) 2023-01-18
SG11202111058XA (en) 2021-11-29
ZA202107499B (en) 2022-06-29
IL287120A (en) 2021-12-01
KR20210151887A (ko) 2021-12-14
US12358896B2 (en) 2025-07-15
MA55624A (fr) 2022-02-16

Similar Documents

Publication Publication Date Title
CO2021010490A2 (es) Compuestos, composiciones y métodos
MX2023003989A (es) Compuestos, composiciones y metodos.
DOP2022000088A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
UY39642A (es) Compuestos heterocíclicos antivirales
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
CL2024003460A1 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.
EA202192530A1 (ru) Соединения, композиции и способы
MX2022005199A (es) Inhibidores de ssao y uso de los mismos.
DOP2021000028A (es) Formulaciones de dendrímeros
UY40440A (es) Inhibidores de la quinasa 7 dependientes de ciclina
AR118379A1 (es) Derivados de benzodiazepinas como inhibidores del rsv
AR133855A1 (es) Compuestos de amina sustituida, composiciones y métodos de uso
AR117112A1 (es) Moduladores de hemoglobina
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
AR122280A1 (es) Compuestos heterocíclicos antivirales